ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

The Development of Prophage G-200 Vaccine for Recurrent Glioblastoma Multiforme

Andrew T. Parsa MD, PhD
Published Online:6:46 PM, Fri June 14, 2013


Andrew T. Parsa MD, PhD, Associate Professor in Residence of Neurological Surgery, University of California, San Francisco, describes the development and clinical trial involving prophage G-200.

Prophage G-200 is an autologous, patient-specific vaccine used to provoke an immune response in patients with recurrent glioblastoma multiforme. The ongoing phase II study, sponsored by the Alliance for Clinical Trials in Oncology, a cooperative group of the National Cancer Institute, looks to answer the question of whether prophage G-200 can facilitate long term overall survival.

There are a number of vaccines, Parsa points out, that are being used and tested in this space. This vaccine is unique because it is polyvalent, with multiple antigens targeting the immune response against cancer cells. In prophage G-200, the patient's tissue makes the vaccine and does not require the isolation, pulsing, and subsequent administration of dendritic cells. Prophage G-200 is the best vaccine in this space because it has all the components to facilitate long-term immunity, Parsa believes.

Clinical Pearls I

  • Prophage G-200 is an autologous, patient-specific vaccine used to provoke an immune response in patients with recurrent glioblastoma multiforme
  • The phase II study, sponsored by the Alliance for Clinical Trials in Oncology, looks to answer the question of whether prophage G-200 can facilitate long term overall survival

Clinical Pearls II

  • There are a number of vaccines being used and tested in this space
  • Prophage G-200 is a unique vaccine because it is polyvalent: It has multiple antigens that it uses to target the immune response against cancer cells

<<< View all coverage from the 2013 ASCO Meeting

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.